Navigation Links
A new target for cancer and diabetes: A novel role for the adaptor protein p66shc in regulating glucose metabolism
Date:2/14/2014

[TORONTO,Canada, Feb 18, 2014] A protein that has been known until recently as part of a complex communication network within the cell also plays a direct role in regulating sugar metabolism, according to a new study published in the journal Science Signaling (February 18, 2014).

Cell growth and metabolism are tightly controlled processes in our cells. When these functions are disturbed, diseases such as cancer and diabetes occur. Mohamed Soliman, a PhD candidate at the Lunenfeld Tanenbaum Research Institute at Mount Sinai Hospital, found a unique role for the p66Shc adaptor protein in regulating glucose metabolism and cell growth. This report could lay the foundation for future studies to target adaptor proteins in cancer and diabetes therapy.

Proteins are functional units of cells that assemble in a precise manner to control cellular processes. Specifically, adapter proteins act as linkers or switches to fine tune cellular functions. Soliman and colleagues became interested in studying the p66Shc adaptor protein following observations regarding the role of this protein as a mediator of insulin sensitivity and longevity. Mice deficient in p66Shc have a greatly increased lifespan and show no signs of cancer. These mice also have better glucose tolerance and are resistant to the development of obesity and diabetes. The findings prompted Soliman to take novel approaches to elucidate the mechanism for this. Soliman comments "we found that silencing the adaptor p66Shc in cells, enhances not only glucose metabolism, but also the metabolism of molecules involved in the making the cells building blocks, resulting in overall increased cell growth."

Thus, p66Shc may have evolved to be a switch that responds to nutrient availability. This role for p66Shc as a sensor of energy levels appears to be unique to higher level organisms. Solimans current mentor, Dr. Jim Dennis, explains "the gene responsible for p66Shc protein expression is relatively new by evolution standards, as it is not seen in species other than vertebrates". Simply stated, p66Shc acts to suppress insulin signaling and energy metabolism when glucose levels are high, as in the case of diabetes.

Mohamed Soliman is a Vanier scholar and was mentored by the late Dr. Tony Pawson whose research is credited for pioneering the field of signal transduction. Dr. Pawson was the first to describe in the 1980's that proteins contain modular domains that allow them to interact with each other to control cellular communication. Mohamed is currently completing his PhD in the laboratory of Dr. Jim Dennis, a Senior Investigator at the Lunenfeld-Tanenbaum Research Institute, and a professor at the University of Toronto. This study has been done in collaboration with Dr. David Sabatini at the Massachusetts Institute of Technology.


'/>"/>

Contact: Mohamed Soliman
ma.soliman@utoronto.ca
Lunenfeld-Tanenbaum Research Institute
Source:Eurekalert  

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. First targeted nanomedicine to enter human clinical studies
3. SMART heart eases heart ache, targets cardiac patients emotional well-being
4. Target set on cancer gene MCL1
5. Scientists tailor cell surface targeting system to hit organelle ZIP codes
6. IBN discovers human neural stem cells with tumor targeting ability
7. A closer look at PARP-1 reveals potential new drug targets
8. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
9. Breathing during radiotherapy - how to hit the treatment target without causing collateral damage
10. Scientists identify new target to battle rheumatoid arthritis
11. Scientists identify possible drug target for acute pancreatitis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A new target for cancer and diabetes: A novel role for the adaptor protein p66shc in regulating glucose metabolism
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 04, 2016 , ... "Pro3rd Displace is a set of ... displacement design elements," said Christina Austin - CEO of Pixel Film Studios. ... of design styles that include both left aligned and right aligned options for ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... 02, 2016 , ... Advanced Inc., a leading provider of travel therapy and ... to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously ... financial and operational leadership experience to Advanced Inc. He began his career in finance ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... N.J. , Dec. 3, 2016  Findings ... and safety of CTL019, an investigational chimeric antigen ... (r/r) pediatric and young adult patients with B-cell ... during an oral session at the 58th American ... December 3, 4:00-5:30 p.m.). The global Phase II ...
(Date:12/2/2016)... bioLytical Laboratories, un líder mundial en test rápidos de ... Self Test , a los miembros de la Kenya Pharmaceutical Association. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la Clinton ...
(Date:12/2/2016)... According to the latest market report ... Automated Endoscope Reprocessors: Single Basin Automated Endoscope Reprocessors Product Type ... and 2024 " the global automated endoscope reprocessors market was valued at US$ ... a CAGR of 7.2% during an eight-year forecast period 2016-2024, ... 2024. ...
Breaking Medicine Technology: